* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download annual report
Survey
Document related concepts
Whooping cough wikipedia , lookup
Marburg virus disease wikipedia , lookup
Meningococcal disease wikipedia , lookup
Onchocerciasis wikipedia , lookup
Schistosomiasis wikipedia , lookup
Leptospirosis wikipedia , lookup
Neisseria meningitidis wikipedia , lookup
Tuberculosis wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Chagas disease wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Neglected tropical diseases wikipedia , lookup
Transcript
Transforming Science into Global Health Solutions Annual Report 2013 Today, millions of people around the world are living with devastating infectious diseases. IDRI is on a mission to change that. 1616 Eastlake Ave. East, Suite 400 Seattle, WA 98102, USA 206.381.0883 • www.idri.org Who is IDRI Founded in 1993 by Steven G. Reed, PhD, IDRI (Infectious Disease Research Institute) is a 501(c)(3) non-profit organization dedicated to the eradication of infectious diseases. Our mission is to develop comprehensive field friendly solutions, including low-cost diagnostics, vaccines and drugs in three key disease areas: tuberculosis, leprosy and leishmaniasis. What sets IDRI apart is our comprehensive approach to address infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company. And, IDRI is a world leader in the development of adjuvants, a key component of vaccine development. Headquartered in Seattle, IDRI collaborates with key partners around the world, including in-country development and commercialization partners, as we believe that the best place to develop new products are in the countries where the diseases we tackle are endemic. Over the past 20 years, IDRI has made remarkable success towards providing low-cost solutions that significantly reduce the global burden of disease – and IDRI’s pipeline of products is expected to save millions of lives. Facilities In May 2013, IDRI moved into a new home in Seattle’s South Lake Union neighborhood, a growing hub for global health/life sciences. Housing over 120 employees, 80 percent of whom are scientists (including more than 50 PhDs/MDs), this space has substantial internal core laboratory and manufacturing competencies – including drug screening, protein expression, assay development and testing, vivarium facilities, BSL2/3 facilities and others. Capabilities IDRI has the capacity and expertise to originate, coordinate and execute preclinical and clinical programs, with the infrastructure required for financial compliance, scientific reporting, and other obligations required for productive collaborations and the broad dissemination of results. Our capabilities include: • • • • • Drug Discovery Antigen Discovery and Expression Adjuvants and Formulations Development Process Sciences GMP Manufacturing • • • • • Quality Assurance/Quality Control Clinical/Regulatory Human Immune Monitoring Diagnostic Test Development Comprehensive Project Management Celebrating 20 Years As IDRI celebrates its 20th anniversary this year, we are proud of what we’ve accomplished and look forward to what the next decades bring as we continue our mission to develop products that will improve health. We believe good health brings a world of possibilities: thriving families, flourishing communities and stable economies. A Letter From H. Stewart Parker Chief Executive Officer 2013 is a banner year for IDRI, as we celebrate our 20th anniversary along with a new home. As you read this report, you’ll learn more about our achievements and plans for the future. In 2011, I joined IDRI because I believe in this organization’s unique, high-impact approach to global health. The result is solutions – in the form of products – for millions burdened by devastating infectious diseases. As CEO, my goal is developing resources – financial, human and physical – to support IDRI’s world-class research and the outstanding scientists you’ll read about in this report. Earlier this year, we took yet another step toward that goal as we moved into new headquarters in Seattle’s South Lake Union neighborhood, allowing us to strengthen our research, development and translational science programs and accelerate our work. This marks an important milestone in IDRI’s 20-year history. IDRI’s success of the past two decades is due to many factors, and one of those is you: our donors, funders, colleagues, partners and advocates. Thank you for your support. Working together, we will ensure IDRI’s continued success. Sincerely, H. Stewart Parker H. Stewart Parker, MBA Chief Executive Officer 1 A Letter From David J. Maki A Letter From Steven G. Reed Chair, Board of Directors Founder, President and Chief Scientific Officer I’m privileged to be associated with IDRI, an organization that takes a comprehensive approach to the treatment and prevention of infectious diseases. In 1993, I established IDRI in order to apply advances in immunology to the development of novel diagnostics, vaccines, and therapeutic products that could transform the lives of the millions of people at risk for infectious diseases throughout the developing world. I haven’t looked back since. Developing products that solve intractable global health challenges is IDRI’s reason for being, and we work passionately to provide solutions that positively impact the world’s most underserved populations. After 20 years, IDRI has concrete progress to celebrate: diagnostics on the market, vaccines in clinical trials and drugs in development. I’m confident that our success in this mission will continue, in large part due to the trusted long-term relationships IDRI has forged in the academic world, with biotech and large pharma, throughout the non-profit ecosystem and with the world’s medical research agencies. These meaningful alliances provide us with unprecedented access to cutting-edge technology and financial support that will extend our efforts for our second 20 years and beyond. This is what IDRI can do. This is what IDRI is doing. And this is what IDRI will continue to do. David J. Maki, JD Chair, Board of Directors 2 Sincerely, David J. Maki Since IDRI’s founding, we have attracted a dedicated team of scientists who have keen minds, compassionate hearts and entrepreneurial spirits. Together, we have created a unique institution that has the flexibility to collaborate with a diverse group of partners, bringing resources together to solve difficult global health challenges. IDRI was founded to develop products that save lives, and I’m proud of what we have done to achieve that goal over the past 20 years. Now, I look forward to what the future holds: the next generation of vaccines, made more powerful by adjuvants; diagnostics enabled by the latest technology; and drugs that can battle the rise of drug-resistant pathogens. Sincerely, Steven G. Reed Steven G. Reed, PhD Founder, President and Chief Scientific Officer 3 THE IDRI SCIENTIFIC PRODUCT PIPELINE From basic research to real world global health solutions DISCOVERY CLINICAL PRECLINICAL Phase 1 Phase 2 Phase 3 MARKET Vaccines Leishmaniasis (Human) Leishmaniasis (Canine) Tuberculosis Leprosy Drugs Tuberculosis Prism Chagas/Architect Chagas* Chagas Detect/Chagas Detect ELISA**, Bioelisa Chagas*** Diagnostics Kalazar Detect™**, DiaMed –IT LEISH®**** Chagas Leishmaniasis Leishmaniasis, 2nd gen Leishmaniasis, test of cure NDO-LID***** Tuberculosis *Licensed by Abbott Laboratories, **Licensed by InBios International, Inc., ***Licensed by Biokit, ****Licensed by Bio-Rad, *****Licensed by OrangeLife Leprosy Areas of Focus Tuberculosis: a bacterial disease that kills nearly 2 million people per year and infects one-third of the world’s population, attacking the lungs, kidneys, spine and brain. Cases of extreme drug resistant (XDR) and multidrug-resistant (MDR) TB are increasing rapidly, and some cases of totally drug-resistant TB have been reported in several countries. Leishmaniasis: a parasitic disease caused by the bite of a sand fly; threatens 350 million people in 88 countries. Most deadly form is visceral, which affects vital organs and bone marrow and destroys blood cells. Available drugs are toxic, expensive and require long-term daily injections. 4 Leprosy: a chronic infectious disease that remains endemic in 24 countries. Thought to be transmitted by a respiratory route, leprosy causes progressive skin sores, nerve damage, loss of muscle control and blindness. There has been no reliable diagnostic available that can detect the disease before the onset of advanced disease symptoms, and no vaccine exists to prevent the spread of the disease. Chagas: a parasitic disease, commonly transmitted through insects, blood transfusions or from mother to baby during pregnancy. If left untreated, the disease usually impairs the heart and digestive system. It is estimated that as many as 8 to 11 million people in Mexico, Central America and South America are infected with Chagas. Adjuvants: Overlaid on these disease targets is a focus on the development of adjuvants, which have broad applicability and are key to the development of successful, low-cost vaccines. Through worldwide collaborations, IDRI makes its adjuvants widely available for use in multiple disease programs, including HIV, malaria, schistosomiasis and others. 5 Discovery Passion – one of the distinctive traits of a scientist. Tanya Parish, PhD, has it in spades. Parish, Vice President of Drug Discovery for IDRI, speaks with great passion on a number of topics: soccer (she is an avid Arsenal fan turned Seattle Sounders supporter); cricket (she readily describes the intricate rules of the game); opera (La Bohème is a favorite). Her biggest passion? Finding new drugs to combat an age-old disease – tuberculosis. “The huge resurgence of TB in the developed world, along with TB’s toll on developing countries and the rise of drug-resistant TB, adds to the great need for new drugs to combat this disease,” said Parish. Most importantly to her, TB is an issue of lost opportunity. “TB is often compounded by poverty, which limits access to the drugs,” she said. “And, the length of therapy for current TB drugs creates an even greater burden for those in developing countries.” Parish, who comes from a TB microbiology background, was a natural fit to lead IDRI’s TB drug discovery efforts. UNIQUE OPPORTUNITY IDRI’s drug discovery efforts are focused on testing thousands of potential drugs in its screening facility – often using robots to speed the process – to find new compounds that kill the bacteria that cause TB. “One of the key issues with TB is its cell wall, which has a thick, waxy coating, making it hard for compounds to penetrate,” explained Parish. “We’re working on ways to overcome that.” While IDRI has focused on TB for many years, the emphasis was primarily on vaccines and diagnostics. Drug discovery was a natural next step, and soon a unique opportunity was presented. When Eli Lilly purchased Washington-based Icos in 2007, Lilly wanted to continue its work on TB. Through a partnership forged by IDRI President and Founder Steve Reed, IDRI acquired equipment, supplies and personnel from Icos/Lilly, along with access to Lilly’s comprehensive compound library to screen for hits against TB. The ultimate goal: developing drugs that are faster acting and cost effective. 6 Today, IDRI has leadership roles in two distinct consortia focused on finding new drugs to combat tuberculosis: the Lilly TB Drug Discovery Initiative and the TB Drug Accelerator, funded by the Bill & Melinda Gates Foundation. TESTING, TESTING Within a multi-disciplinary approach, chemists develop new molecules, then biologists test those to determine what works against TB and why. “This approach – working as a team, not as individuals – makes it all happen,” said Parish. “The quicker we can test and refine, the quicker we’ll have new drugs to combat TB.” IDRI’s DISCOVERY EFFORTS Tuberculosis • Characterized molecular targets to better understand the specific host immune responses to TB. • Produced world’s largest collection of TB antigens and screened them for promising prophylactic, therapeutic and diagnostic potential. • Screened thousands of compounds for hits against TB with the goal of developing new drugs to shorten therapy and combat drug resistance. Leishmaniasis • Produced world’s largest collection of leishmaniasis antigens, promising for prophylactic and diagnostic applications. Leprosy • Produced world’s largest collection of leprosy antigens and screened them for promising prophylactic, therapeutic and diagnostic potential. • Designed the first leprosy vaccine candidate. Adjuvants • Established a world class library of adjuvant molecules and formulations. Animal Vaccines • Entered into numerous collaborations to design a range of animal vaccines to improve animal health. Tanya Parish, PhD “The huge resurgence of TB in the developed world, along with TB’s toll on developing countries and the rise of drug-resistant TB, adds to the great need for new drugs to combat this disease.” 7 What is an Adjuvant? An adjuvant is a substance added to a vaccine to increase the body’s immune response. “Adjuvant” comes from the Latin word adiuvare, meaning “to help.” And, that’s just what these substances do by boosting immune response, broadening vaccine protection and reducing the amount of antigen and/or injections needed. A world leader in adjuvant development, IDRI produces adjuvants that are used in our own vaccines for leishmaniasis and tuberculosis, as well as in vaccines our partners are developing for HIV/AIDS, malaria, hookworm, pandemic influenza and other diseases. Darrick Carter, PhD OVERVIEW: IDRI’s DEVELOPMENT EFFORTS Vaccine Clinical Trials IDRI’s Recent & Ongoing Clinical Trials IDRI’s Vaccines (Funder/Site) Disease Area Clinical Phase LEISHF3+GLA-SE (BMGF*/Washington) Leishmaniasis 1 LEISHF3+GLA-SE (NIH/Iowa) 1 Leishmaniasis ID93+GLA-SE (BMGF/Kansas) Tuberculosis 1 ID93+GLA-SE (BMGF/South Africa) Tuberculosis 1b ID93+GLA-SE (Wellcome Trust/ South Africa) Tuberculosis 2 Ongoing Clinical Trials of IDRI Collaborators IDRI adjuvant formulations developed and manufactured under cGMP conditions are currently in use by our partners in more than 10 clinical trials in the U.S. and abroad. *Bill & Melinda Gates Foundation 8 Tuberculosis • Developed the first molecularly defined vaccines against TB, and are moving its lead TB vaccine candidate (ID93+GLA-SE) from initial clinical trials in the U.S. to trials in countries where TB is endemic. Leishmaniasis • Developed the first pipeline of vaccines against leishmaniasis, conducted numerous clinical trials, and partnered its lead vaccine candidate (LEISHF3+GLASE) with an India based company (Zydus Cadilla) to conduct clinical trials and bring the vaccine to market in countries where the disease is endemic. • Developed a second generation diagnostic tool, which will be a low cost body fluid diagnostic test for asymptomatic case detection. It can also monitor cure with treatment (critical for disease elimination). Collaborations • Transferred key technologies to partners in developing countries, including to Romania and India. Leprosy • Developing a T-cell based test to determine which of the people shown to be infected (using IDRI’s already registered antibody test) are likely to self-cure or otherwise develop specific types of active disease. This ensures appropriate case management and therapeutic treatment. Adjuvants • Provided broad access to its library of adjuvants and adjuvant formulation expertise to support third parties’ development of a wide range of vaccines, including those for HIV, influenza, malaria, hookworm and other diseases. Animal Vaccines • Developed canine leishmaniasis vaccines in collaboration with partners, using IDRI designed recombinant-protein antigens and its proprietary adjuvants, to support animal health and human disease control. Preclinical and Clinical Rhea Coler, PhD, recalls a shyly smiling boy, standing beside her at a hospital in Ethiopia. He was being treated for leishmaniasis, a disease that has serious consequences – ranging from severe scarring to death – dependent on its form. But the effects are even more farreaching. “Abraham and his father, who stayed with him in the hospital, were separated from the rest of their family for several weeks,” explained Coler, Vice President of Preclinical Biology at IDRI. She also pointed out that by caring for his son, Abraham’s father was unable to work, creating another burden for their family. Leishmaniasis is one of several devastating infectious diseases that do not have viable vaccines for either prevention or treatment. IDRI is working to change that, with pre-clinical studies and clinical trials under way for vaccines to combat leishmaniasis, tuberculosis and leprosy. The Long Road of Development Rhea Coler, PhD An incredible amount of work and energy are needed to design vaccines and see them successfully through the development cycle. IDRI screens and tests hundreds of recombinant proteins as potential vaccine candidates. “We have identified and successfully characterized several proteins that have been studied across multiple animal models and human cells,” said Coler. From there, scientists develop vaccine candidates, composed of IDRI designed recombinant fusionprotein antigens plus IDRI’s proprietary adjuvants. adjuvant, LEISH-F3 has produced an immune response and is protective against infection from at least two different forms of Leishmania parasites,” explained Coler. Creating a Vaccine for Leishmaniasis With promising preclinical results, IDRI received approval from the U.S. Food & Drug Administration (FDA) to conduct Phase I clinical trials in the U.S. to evaluate its vaccine candidate in healthy adult volunteers. Trials in Tacoma, WA, and Iowa City, IA, are ending, and safety and immunogenicity data are being generated. For IDRI’s leishmaniasis vaccine, preclinical studies in animal models resulted in the identification of two prominent Leishmania proteins, leading to the development of a unique fusion protein called LEISH-F3. “When coupled with our GLA-SE “The data from the U.S. trials provides direction for our next step – trials in countries such as India, Bangladesh and Sudan where prevalence is high and the need for an effective vaccine is of utmost importance,” said Coler. 9 To Market Steven Reed, PhD Early in his career, IDRI founder Steven Reed traveled to Brazil and observed something that set the course for his life’s work and forged the basis of IDRI’s mission. Time again, he saw children being forcibly held down to test for leishmaniasis, a parasitic disease caused by the bite of a sand fly. “At that time, diagnosis consisted of putting a needle in a kid’s sternum or spleen to look for parasites,” Reed explained. “There had to be a better way.” And today there is, because of Reed’s vision and hard work. IDRI’s diagnostic requires just a single drop of blood, with results appearing within minutes. “I’m happy to say the test is being used now, around the world, and is saving lives,” said Reed. In fact, on a recent trip to Bangladesh, Reed visited a hospital where, on a list of tests provided by the hospital, IDRI’s leishmaniasis diagnostic appeared, free of charge. But IDRI hasn’t stopped at developing a diagnostic for just one disease. Chagas: Screening the U.S. Blood Supply While most commonly spread by the bite of an insect called the “kissing bug,” Chagas disease, a parasitic disease prevalent in Latin America often resulting in serious heart and digestive issues, 10 can also be passed through infected blood. IDRI developed technology to diagnose Chagas. That technology has been incorporated into a test, created by Abbott Laboratories, to identify whether T. cruzi (the parasite that causes Chagas) contaminates any portion of the blood supply. “Blood donations in Latin American countries where Chagas is endemic have undergone screening for many years,” explained Reed. “Now countries, such as the U.S. that have growing populations who come from endemic areas, are recognizing the threat and testing all donated blood and tissues.” Leprosy: A Modern-Day Threat Earlier this year, IDRI registered another test for use in Brazil, offering new hope for early diagnosis and treatment of people infected with leprosy. An ailment most people associate with biblical times, leprosy is a chronic infectious disease prevalent in countries throughout Africa, Asia and South America – including Brazil. And there are reports of leprosy infection, carried by armadillos, in the southern U.S. “Currently the method of detection for leprosy is by clinical and/or microscopic assessment,” explained Reed. “There is a great need to more rapidly diagnose infection, before nerve damage occurs.” According to Malcolm Duthie, Senior Scientist at IDRI, the leprosy diagnostic test is simple and easy to use. “The test, which could detect infection up to a year before disease symptoms occur, requires just a single drop of blood, mixed with a developing reagent,” he explained. “From there, a line develops and it’s somewhat like a pregnancy test: the appearance of two lines indicates the test is positive.” The first step to ending an infectious disease is accurately and rapidly diagnosing it. “Having our diagnostics on the market and available for use is one of IDRI’s greatest successes of the past 20 years,” said Reed. IDRI’s APPROVED PRODUCTS Chagas • Licensed technologies to Abbott Laboratories for the development of a test to detect infection of T. Cruzi, the causative agent of Chagas disease. The test is marketed throughout North and South America, including its use to protect the U.S. blood supply. Leishmaniasis • Partnered with multiple commercial entities in the U.S., Africa, India and Brazil, to license our technology for the development and commercialization of very low-cost, rapid diagnostic tests for leishmaniasis. These tests are approved and registered in endemic countries. Leprosy • Licensed technology to our Brazilian diagnostics partner, OrangeLife, for the development and commercialization of an antibody diagnostic to detect infection of M. leprae, the causative agent of leprosy, in advance of clinical symptoms. This test is approved and registered in Brazil. 11 Our Team Financials BOARD OF DIRECTORS EXECUTIVE LEADERSHIP Eric Easom, MBA Anna Marie Beckmann, PhD Rob Lin, PhD, CFA Christopher Hentschel, PhD David J. Maki, JD Darrick Carter, PhD Curt Malloy, JD, MPH H. Stewart Parker, MBA David Perry, MBA Franklyn G. Prendergast, MD, PhD Massimo Radaelli, PhD Steven G. Reed, PhD David Webster, MBA Vice President, TB Drug Development Immediate Past Chair Chairman & Treasurer Secretary Vice President, Development & Regulatory Vice President, Adjuvant Technology Gail Cassell, PhD Funding Sources Vice President, Drug Discovery H. Stewart Parker, MBA Erik H. Iverson, JD, LLM Steven G. Reed, PhD IDRI now has a 4,000-square-foot, state-of-the-art cGMP manufacturing facility for the formulation and vialing of its library of adjuvants, as well as the following capabilities and capacity for the fill/finish of large or small molecules in liquid, emulsion or liposome formulations: 25% Malaria 49% Vaccines 14% Royalties, Manufacturing & Service Founder, President & Chief Scientific Officer Thomas Vedvick, PhD 3% Individuals Vice President, Formulation & Process Development IDRI’s Manufacturing Capabilities and Capacity With the move earlier this year into its new home, IDRI expanded manufacturing infrastructure to support vaccine development for our work as well as that of our partners. Industry veteran Erik D. Laursen directs IDRI’s GMP operations. 43% Foundations 34% Tuberculosis 12% Drug Discovery Chief Executive Officer Executive Vice President, Business Development & External Affairs Vice President, Administration 27% Adjuvants Senior Vice President, Operations & General Counsel Vice President, Preclinical Biology Karen Kinch By Disease 30% US Government Vice President, Finance Tanya Parish, PhD Rhea N. Coler, PhD By Activity •Formulation development • Analytical development for in-process and release testing •Cell based bioassay •Method verification and qualification •Engineering run for pre-clinical purposes [≤~15,000 vials/batch] •cGMP run for Phase 1 and 2 clinical studies [≤~15,000 vials/batch] •Vial size range: 2-10 mL [with ability to expand to 20 mL] •Labeling of small lots [<2000 vials] •Release testing •Stability study 5% Other Government & NGOs 9% Diagnostics 6% Leprosy 3% Antigens 13% Flu 5% Corporate Funding 22% Leishmaniasis Balance Sheet Statements of Activities 2012 2011 ASSETS Total Current Assets 31,871,965 35,084,600 Property and equipment, net 9,478,710 1,951,709 Pledges receivable - long term 7,972,481 4,814,605 Investment - long term 215,000 577,410 Total Assets 49,538,156 42,428,324 LIABILITIES AND NET ASSETS Total Liabilities 12,130,421 3,595,070 Net Assets Unrestricted 3,085,312 2,908,320 Temporarily Restricted 34,322,423 35,924,934 Total Net Assets 37,407,735 38,833,254 Total Liabilities and Net Assets 49,538,156 42,428,324 2012 REVENUES Public Support 7,517,219 Private grants and contributions 13,845,150 Earned Income 3,089,456 Investment and other revenues 442,209 2011 8,427,006 11,944,226 2,255,625 135,088 Total Revenues 24,894,034 22,761,945 EXPENSES Program expenses 20,000,794 19,403,333 Management and General expenses 4,412,113 3,322,898 Fundraising 304,135 166,464 Total Expenses Change in Unrestricted Net Assets 24,717,042 22,892,695 176,992 (130,750) FOR THE YEAR ENDING DECEMBER 31, 2012 Audited financial statements available upon request. Making IDRI Technologies Available to Support Global Health Investing in Ourselves for the Future Erik Iverson, JD, LLM Executive Vice President, Business Development & External Affairs Funding sources for non-profits typically include foundations, government and individuals. However, it’s a bit unusual to see “royalties, manufacturing and service” cited as revenue streams. This helps distinguish IDRI as we invest in our organization for the future. In 1980, the U.S. Bayh-Dole Act was passed, permitting universities and non-profit institutions to own inventions resulting from federally funded research. IDRI follows this model to further 12 develop our technologies into life-saving products, and to generate licensing revenues to complement grant funds to support our global health mission. With specific products in development, and widely applicable diagnostic and vaccine technologies, IDRI has licensed out products and technologies to pharmaceutical and biotechnology companies while reserving rights necessary to continue the development of products for global health. The benefits to IDRI are twofold. First, IDRI receives licensing revenues used to support our charitable mission programs in tuberculosis, leishmaniasis and leprosy. Second, the scientific studies conducted by the companies and funded by private investment provide critically important data used by IDRI scientists to strengthen our global health programs. We’ll continue to seek new opportunities to make our technologies available to support the achievement of our primary goal – to transform our science into global health solutions. 13 COLLABORATORS FUNDING PARTNERS Abbott Laboratories Instituto Butantan Academia Sinica Instituto de Biomedicina Cape Town, South Africa Addis Ababa University Instituto de Infectologia Emilio Ribas London, UK Aeras Iowa State University Geneva, Switzerland Anandaban Hospital Istituto Superiore di Sanita College Station, TX Bio-Rad Laboratory of Malaria Immunology and Vaccinology/NIH Kerala, India Bethesda, MD UK Consortium on AIDS and International Development Laboratory of Malaria Vector Research/NIH London, UK UK HIV Vaccine Consortium LSU Veterinary School of Medicine Universidad del Valle Massachusetts Institute of Technology Universidade Federal de Goiás Chicago, IL Taipei, Taiwan Addis Ababa, Ethiopia Rockville, MD Kathmandu, Nepal Canton, OH Bio Veto Test La Seyne-sur-Mer, France Cantacuzino Institute Bucharest, Romania Case Western Reserve University Cleveland, OH Cebu Leprosy and Tuberculosis Research Foundation Cebu, Philippines Centers for Disease Control and Prevention Atlanta, GA Chembio Diagnostics Systems, Inc. Medford, NY Colorado State University Fort Collins, CO CTK Biotech, Inc. San Diego, CA EASE-Medtrend Shanghai, China Elanco Indianapolis, IN Eli Lilly & Co. Indianapolis, IN European Vaccive Initiative Heidelberg, Germany Fraunhofer Center for Molecular Biotechnology Newark, NJ Gennova Biopharmaceuticals Pune, India ICDDR,B Dhaka, Bangladesh Immune Design Corporation Seattle, WA Imperial College London London, England InBios International Seattle, WA Institute of Endemic Diseases Khartoum, Sudan Institute of Human Virology Baltimore, MD 14 Sao Paulo, Brazil Caracas, Venezuela Sao Paulo, Brazil Ames, IA Rome, Italy Bethesda, MD Baton Rouge, LA Cambridge, MA MCRF/Institute of Microbial Chemistry Tokyo, Japan Medicago Quebec, Canada Merck Whitehouse Station, NJ South African Tuberculosis Vaccine Initiative St George’s University of London TDR | WHO Texas A&M ubio London, UK Cali, Columbia Goiás, Brazil Universidade Federal da Bahia Salvador, Brazil Universidade Federal de Sergipe Sergipe, Brazil Universidade Federal de Minas Gerais Belo Horizonte, Brazil Merial Universidad Peruana Cayetano Heredia NanoPass University of Banaras National Hansen’s Disease Program University of Delhi National Institute of Infectious Diseases University of Hawaii Duluth, GA and Lyon, France Nes Ziona, Israel Baton Rouge, LA Tokyo, Japan OrangeLife Rio de Janeiro, Brazil Oswaldo Cruz Foundation-FIOCRUZ Rio de Janeiro, Brazil PECET Universidad de Antioquia Medellin, Columbia Research Triangle International Research Triangle Park, NC Lima, Peru Varanasi, India Delhi, India Honolulu, HI University of Iowa Iowa City, IO University of Texas Medical Branch Galveston, Tx University of Tokyo Tokyo, Japan USAID Washington D.C. Rockefeller University Walter Reed Army Institute of Research Sabin Vaccine Institute Weill Cornell Medical College Seattle BioMed Zydus Cadila New York, NY Washington, DC Seattle, WA Silver Spring, MD New York, NY Ahmedabad, India American Leprosy Mission Army Research Organization (ARO) / DARPA European Commission BARDA Murdock Charitable Trust National Institutes of Health/ National Institute of Allergy & Infectious Disease New York Community Trust / Heiser Program (Defense Advanced Research Projects Agency) (Biomedical Advanced Research and Development Authority) Bill & Melinda Gates Foundation CRDF Global Eli Lilly & Co. (Party with a Purpose) The Wellcome Trust Individuals Anonymous (2) Sherry Adams Andy Anderson Fred & Thuan Angeles Cheryl & Chris Antony Mary Rae Armantrout Bill & Pamela Ayer Rip Ballou & Alice Grasset Kristin Beaulieu Paul Blair Gregg & Jane Blodgett Carolyn Booth Stanson Ryan Brown Delphi Chatterjee Ines & Jay Clark Rebecca Clark Therese Coad Jessica Cohen Rhea & Clark Coler Genevieve Cseh Brian Curtis Walter Curtis Erik Cutts Jeff Dixon Katherine Duncan Corporations Statens Serum Institute Aedas BioLegend BNBuilders Copenhagen, Denmark Norcliffe Foundation PATH Vaccine Solutions (PVS) PATH The Paul G. Allen Family Foundation Renaissance Health Service Corp. Washington Global Health Alliance HONOR ROLL OF DONORS Span Diagnostics Surat, India (as part of the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities) Ken Duncan Sharon Early Eric Easom Jean Feagin Norman Ferrer Edmee Files Tom Fleszar Benjamin & Griselda Gay Joshua Halverson Fred Hapgood Erik Iverson Ed Kesicki Aaron Korkegian Kenneth Lee Rob Lin James R. Lisbakken LNGC Dave Maki Curt & Ana Malloy Karina Martens Jennifer & Mike Mortensen Helen & Ron Ness Kelly O’Malley John & Molly Otter Yulia Ovechkina Lynda Paleshnuik Cherry Parish Gina Parish Tanya Parish Stewart Parker Jeremy Peterson Jon Peterson Trang Pham Franklyn G. Prendergast Marianne & Steve Reed Lee & Will Schoentrup Sandlin Sequin Laura Shoemaker & Morgan Woolverton Sanjay Singh Susan Steinbach-Molloy Giles Strekel Tom & Claudia Vedvick David Webster Carl Weissman Winston Wicomb Tadataka Yamada Ying Yu Fisher Scientific GlaxoSmithKline Mary North Travel Wells Fargo Insurance Services 15 Join us. MISSION We apply innovative science to develop products to eliminate infectious diseases of global importance. VISION The Power of One The power of one is impressive, even in the face of a challenge as daunting as global health. Throughout this annual report, you’ve read about the power of people who make a positive difference in the lives of millions who bear the burden of infectious diseases. Now we invite you to consider how you can contribute to improve global health. It’s simple. • Tell someone about what you learned by reading this report. • Visit our website at www.idri.org to learn more or to sign up for our electronic newsletter. • Attend an IDRI event. • Invite an IDRI scientist to speak at an educational or civic event. • Donate to support our research and product development efforts. We believe in the power of one – your contribution will improve the lives of many. With good health comes a world of possibilities: thriving families, flourishing communities and stable economies. 1616 Eastlake Ave. East, Suite 400 Seattle, WA 98102, USA 206.381.0883 • www.idri.org We envision a world in which infectious diseases are either prevented or rapidly diagnosed and treated using products that are available to all people. WE VALUE: Compassion: We are driven by compassion and the belief that all people should be free from infectious diseases, which cause untold death and suffering. Our work holds the promise of saving millions of lives and improving the quality of life around the world. Scientific Excellence: We are rooted in scientific excellence. We are committed to the diligence, integrity and ethics required to conduct research and develop products in a responsible, efficient manner. Impact: We believe our research and product development will have significant, positive impact for the benefit of the world’s most underserved populations. Through collaboration and innovation, we bridge knowledge and action to reduce suffering and save lives.